Compare CLS & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLS | RMD |
|---|---|---|
| Founded | 1994 | 1989 |
| Country | Canada | United States |
| Employees | N/A | 10600 |
| Industry | Electrical Products | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.7B | 32.2B |
| IPO Year | 1999 | N/A |
| Metric | CLS | RMD |
|---|---|---|
| Price | $410.28 | $219.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 10 |
| Target Price | ★ $354.93 | $293.56 |
| AVG Volume (30 Days) | ★ 2.0M | 860.8K |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.09% |
| EPS Growth | ★ 98.34 | N/A |
| EPS | ★ 7.16 | N/A |
| Revenue | ★ $12,390,900,000.00 | N/A |
| Revenue This Year | $41.81 | $10.60 |
| Revenue Next Year | $39.95 | $7.41 |
| P/E Ratio | $57.23 | ★ $25.61 |
| Revenue Growth | ★ 28.46 | N/A |
| 52 Week Low | $81.88 | $216.68 |
| 52 Week High | $420.63 | $293.81 |
| Indicator | CLS | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 74.19 | 35.32 |
| Support Level | $264.43 | $218.39 |
| Resistance Level | N/A | $260.21 |
| Average True Range (ATR) | 17.43 | 4.81 |
| MACD | 5.04 | -0.02 |
| Stochastic Oscillator | 91.88 | 15.86 |
Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity & Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, The Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity & Cloud Solutions segment.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.